title: [Safety and efficacy of multiple subpial transections: report of a consecutive series of 30 cases].
abstract: OBJECTIVE
  To present our results using multiple subpial transections (MST) for the treatment of pharmacologically refractory epilepsy (PRE) with epileptogenic foci in eloquent areas.
  
  
  METHODS
  Between January 2003 and March 2006, we treated 33 patients with PRE with epileptogenic foci in eloquent areas by MST "in rays", either isolated (MSTs group) or completing resection or disconnection of other cortical areas (MST+ group). Our first 30 patients had a follow-up of at least 24 months: eight in the MSTs group and 22 in the MST+ group. Four postoperative grades were distinguished based on a modified Engel classification: seizure-free (100% seizure reduction equals to Grade I), substantial significant seizure reduction (75% to 99% seizure reduction equals to Grade II), moderate significant reduction (50% to 74% seizure reduction equals to Grade III) and finally no significant reduction (seizure reduction less than 50% equals to Grade IV).
  
  
  RESULTS
  In the MSTs group, two patients (25%) were in grade I and five (62%) in grade II or III. In the MST+ group, six patients (27%) were in grade I and 13 (59%) in grade II or III. All patients showed some seizure reduction and some improvement in behavior or cognitive function with no permanent neurological deficit.
  
  
  CONCLUSIONS
  This series supports the notion that multiple subpial transections are associated with a significant seizure reduction (in 86.6% of the cases reported herein) and that the risk of permanent neurological deficit can be very low.
authors.affiliation: Département de neurochirurgie, centre de référence pour l'épilepsie pharmacorésistante, cliniques universitaires de Saint-Luc, université catholique de Louvain, avenue Hippocrate 10, 1200 Bruxelles, Belgique.
authors.forename: G
authors.initials: G
authors.lastname: Vaz
authors.forename: Y
authors.initials: Y
authors.lastname: van Raay
authors.forename: K
authors.initials: K
authors.lastname: van Rijckevorsel
authors.forename: M
authors.initials: M
authors.lastname: de Tourtchaninoff
authors.forename: C
authors.initials: C
authors.lastname: Grandin
authors.forename: C
authors.initials: C
authors.lastname: Raftopoulos
mesh_terms: D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use; D001921:Brain / Q000601:surgery*; D002540:Cerebral Cortex / Q000601:surgery; D002648:Child; D002675:Child, Preschool; D004351:Drug Resistance; D004569:Electroencephalography; D004827:Epilepsy / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000601:surgery*; D005260:Female; D019788:Fluorodeoxyglucose F18; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D019635:Neurosurgical Procedures / Q000009:adverse effects; D010841:Pia Mater / Q000601:surgery*; D049268:Positron-Emission Tomography; D011183:Postoperative Complications / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000523:psychology; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D000927:Anticonvulsants; D019788:Fluorodeoxyglucose F18